Cargando…
Molecular Drug Discovery of Single Ginsenoside Compounds as a Potent Bruton’s Tyrosine Kinase Inhibitor
Bruton’s tyrosine kinase (BTK) is known as a direct regulator of inflammasome, which is an intracellular target to therapeutically modulate innate immunity. Although there is great interest in developing small molecule-based drugs with BTK inhibition, there are only a few drugs available in the mark...
Autores principales: | Lee, Keun Woo, Lee, Woong Hee, Han, Baek-Soo, Lee, Jin Ha, Doo, Eun Kyung, Kim, Jeong-Hwan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247683/ https://www.ncbi.nlm.nih.gov/pubmed/32357562 http://dx.doi.org/10.3390/ijms21093065 |
Ejemplares similares
-
Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton’s Tyrosine Kinase
por: Lee, Eun, et al.
Publicado: (2020) -
Discovery
of Potent and Selective Tricyclic Inhibitors of Bruton’s Tyrosine
Kinase with Improved Druglike Properties
por: Wang, Xiaojing, et al.
Publicado: (2017) -
Discovery of Tricyclic Pyranochromenone as Novel Bruton’s Tyrosine Kinase Inhibitors with In Vivo Antirheumatic Activity
por: Cho, Hyewon, et al.
Publicado: (2020) -
Bruton's tyrosine kinase: oncotarget in myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2012) -
Editorial: Targeting Bruton Tyrosine Kinase
por: Brunner, Cornelia, et al.
Publicado: (2022)